Global C-Reactive Protein Testing Market

Global C-Reactive Protein Testing Market Insights:

The global C-reactive protein testing market was estimated to generate revenue of USD 1,513.49 million in 2017, and is estimated to grow at a CAGR of 1.37% from 2019 to 2026. The market growth is driven by rise in prevalence of inflammatory diseases over the world and rising awareness about benefits of C-reactive protein testing. Rising cases of endometriosis in women is also expected to be a potential driver for the growth in the C-reactive protein testing market.

High sensitivity C-reactive protein test is expected to hold the largest market share in terms of revenue during the forecast period. Growth in the segment is driven by the ability of the test to detect high risk cardiovascular diseases accurately. In the assay type segment, the immunoturbidimetric assay segment is expected to dominate the market in terms of revenue, with a forecasted CAGR of 1.69%. The growth is attributed to multiple applications and convenience of the assay.

The cardiovascular diseases segment is expected to lead the market for C-reactive protein testing during the forecast period. The growth can be attributed to multiple applications of C-reactive protein testing in diagnosis of high risk cardiovascular diseases. C-reactive protein testing is extensively used in detection and monitoring of multiple chronic diseases such as rheumatoid arthritis, lupus and inflammatory bowel disease among others.

North America is expected to dominate the market for C-reactive protein testing during the forecast period owing to availability of advanced healthcare facilities, innovation and initiatives taken by the Government to encourage adoption of new technology. The Asia Pacific region is projected to grow at the highest CAGR of 1.82% during the forecast period, owing to substantial development in healthcare in emerging economies.

Request a sample copy of the report @: Global C-Reactive Protein Testing Market

Global C-Reactive Protein Testing Market: Technological Landscape

Technological development in the C-reactive protein testing market is driven by growing adoption and awareness about applications of C-reactive protein testing. C-reactive protein tests essentially measures the level of C-reactive protein in the blood, which is an important market for inflammation in the human body. High levels of C-reactive protein in the body may indicate risk of endometriosis, lupus, rheumatoid arthritis and other cardiovascular diseases. Measurement of C-reactive protein in the body is crucial in diagnosis of the intensity of the disease.

HS-CRP which means high sensitivity C-reactive protein test which is used for measurement of C-reactive protein levels which indicate high risk of cardiovascular disease. This test is highly sensitive to presence of C-reactive protein in the blood which produces more accurate results for diagnosis. CCRP, which is a recently recognized test for measurement of C-reactive protein, is used specially for detection of risk of fatal diseases such as coronary heart disease. The test is also capable of assessing the intensity of strokes and heart attacks, and can help determine the extent of risk. 

Developments in C-reactive protein testing devices enable doctors and medical practitioners to get test results instantly, which reduce the downtime involved in patient diagnosis and prescription of medicines. Point of care C-reactive protein testing devices produce results in a matter of minutes, and enables fast decision making. Adoption of point of care CRP testing devices in private small scale clinics is expected to reduce prescription of antibiotics to a great extent.

Global C-Reactive Protein Testing Market Drivers:

Growing investment in testing devices technology:

The market for C-reactive protein testing is driven by growing investment in testing devices technology. CRP tests are blood tests which measure the presence of C-reactive protein in the human body. Elevated CRP levels indicate inflammation in the body which may be caused due to cardiovascular diseases.

Technological developments in devices used to measure CRP levels in patients are expected to drive the market for C-reactive protein testing. Government initiatives in developed and emerging countries are being taken to encourage adoption of CRP testing in hospitals and other medical facilities. There have been substantial investments in development of new technology to improve adoption and accuracy of CRP testing, which is likely to further drive the market. 

The newly developed paper-based testing takes less than 5 minutes to get results as opposed to the traditional method which takes 3 to 4 hours. Improved technology is expected to facilitate ease of usage and increase penetration of CRP testing devices. In January 2018, Meso Scale Diagnostics received clearance from the FDA for its C-reactive protein assay for in-vitro diagnosis use in the U.S.

Rising incidence of inflammatory disorders:

C-reactive protein tests are used to diagnose inflammatory diseases such as inflammatory bowel disease, endometriosis, cancer, rheumatoid arthritis, cardiovascular diseases, and lupus among others. Elevated CRP coupled with factors such as hypertension, high blood pressure, diabetes and high cholesterol indicates serious heart diseases. Early detection of these diseases helps reduce threat of heart attacks and strokes to a great extent. CRP finds applications in vitro and in vivo development of new compounds for inflammatory disorders. There has been a significant rise in incidence of these diseases in population in developed as well as emerging countries. These factors are expected to drive growth in the CRP testing market. 

Growing cases of endometriosis in women:

Endometriosis is a disorder in which the tissue lining the uterus grows outside the uterus. The disease usually involved the woman’s ovaries, fallopian tubes and the tissue which lines the pelvis. The disease may also spread beyond the pelvic region. Women with endometriosis show high level of sensitivity towards C-reactive protein than those without it. The test is therefore extensively used for detection of the disease in patients. Endometriosis is primarily caused due to retrograde menstruation, Transformation of peritoneal cells, embryonic cell transformation, surgical scar implantation, endometrial cells transport and Immune system disorders. Rising incidence of the disease in women is expected to boost the demand for C-reactive testing.

Check the Press Release on Global C-Reactive Protein Testing Market Report